BioCentury
ARTICLE | Finance

As trio of companies enter IPO queue, four more propose terms

July 21, 2020 3:30 AM UTC

Cross-border licensing company Everest, gene therapy play Freeline and oncology company Checkmate are the latest companies to enter the IPO queue, joining a long list of companies aspiring to go public in a season when investors have shown considerable appetite for new biotech listings.

Last week’s IPOs brought the total IPO cash raised in 2020 to $13.3 billion across 56 biopharma offerings and included the year’s second-largest offering (see “Biotech Trio’s NASDAQ Debuts”; see “Relay’s IPO”)...